Improving the lives of transplant patients
Transplantation is intended to give patients their lives back, but an infection with cytomegalovirus (CMV) triggered by post-transplant immunosuppression may be devastating to patient outcomes.
Our ambition is to improve the life of patients and their ability to enjoy a normal life after transplantation, by reducing the risk of CMV reactivation through treatment of the donor organ prior to transplantation.
OUR AMBITION
We want to establish a market leader position for our products
We want to fuel a pipeline with innovative, differentiated, and highly valuable drug candidates for chronic viral infections, based on our core technology platform. Become a preferred partner for discovery and early clinical development in the chronic infectious diseases space.
OUR WORKING PHILOSOPHY
Advancing scientific excellence towards valuable therapies utilising an exclusive international network
- Our science – focused, balanced & with high impact
- Our therapies – addressing unmet medical needs, with clear differentiation & attractive markets
- Our partners – ambitious, excellent & complementary
OUR VALUE PROPOSITION
Improving the life of transplant patients
Transplantation is intended to give patients their life back, but an infection with cytomegalovirus (CMV) triggered by the transplant conditioning therapy may be devastating to patient outcomes. SYN002 is aimed at improving the life of transplant patients and ensure their ability to enjoy a normal life after transplantation by eliminating the risk of CMV infection in transplant recipients, either by treating the donor organ (ex vivo) prior to transplantation or by treating the recipient after transplantation (in vivo).
Our team
Synklino is led by a management team and board of directors with extensive and international experience across a broad range of disciplines within drug development, business development, financing and governance.
Management
25+ years in life science and biotech. Previous Head of Virology and Life Science Engineering at DTU, DK, CEO at Inagen, Group leader at the National University Hospital and post doc. at Stanford University
Global experience in conducting Phase 1 through Phase 3 drug development, in-depth knowledge of translational immunology and virology research. Comprehensive regulatory experience including submission of multiple CTA and IND applications.
20 years in life science and the biopharmaceutical industry. Highly experienced with development, operations and CMC and previous Senior Director at Symphogen
20 years of pharmaceutical and biotech experience as a financial leader with several CFO positions. Experienced in taking companies public on the Nordic stock exchanges and managing listed companies
20+ years of experience in drug development, project management, discovery, translational science and nonclinical development
Experienced researcher, and project manager with experience from Alligator Bioscience. Previous postdoc at Scripps Research
Board of Directors
35 years of research experience (10 years in Oxford and Cambridge) & 20+ years in biotech. Extensive experience in building and leading biotech companies. Co-founder and former CSO of Symphogen, CEO of F-star Therapeutics
An experienced investor, business angel and board member in a range of mainly life science and medtech companies. Morten is also involved in MC2 Therapeutics, Mermaid Care, MEQU and XO Care
Professor in Translational Pharmacology, University of Copenhagen. Co-founder of Synklino, Antag Therapeutics and Bainan Biotech
Previous CSO at Veloxis, CMO at Cellvie and in senior leadership positions in Astellas Pharma, and Bristol-MyersSquibb
30+ years’ experience in pharmaceutical development and manufacturing. CEO & Co-founder of CMC Biologics, CMO of Symphogen
An entrepreneur with extensive strategic financial management experience within the life science industry. Thomas is cofounder of Saniona, Scandion Oncology Initiator Pharma, Symphogen, and Ataxion. Thomas’ previous roles include CFO of Saniona, CFO of Symphogen and Investment Associate at Novo A/S and Corporate Development Manager at Novo Nordisk
Christine is Senior Vice President, Novo Nordisk with a track record of leading change and delivering im-pact. Christine has end-to-end understanding of the biotech and medtech value chain and broad knowledge of pharmaceutical and business ethics regulations. Christine was member of DTU Advisory board and board of Representatives from 2008 to 2014
Mads is Investment Director at the Danish Growth Fund specialized in medtech companies. Mads is an experienced Digital Health Investor leading some of the Nordics largest capital rounds (amongst other in Corti and Dawn Health). Mads is board member in a number of companies i.e., FreeSense ApS, KUBO Robotics ApS, Dawn Health A/S, Dawn Labs A/S, Dawn Holding ApS, Corti ApS, NewBanking Holding ApS, and NewBanking ApS
Scientific Advisory Board
Deputy Head of the Department of Medicine and Head of the Division of Infectious Diseases at Cambridge University
EVP, CSO, and Distinguished Research Fellow at Immunogen
Senior Scientist, Toronto General Hospital Research Institute. World leading expert in the field of transplantation & infectious diseases